SGS has invested in multiple LC-MS/MS instruments for protein therapy development at laboratory in Poitiers, France
Verification, testing and certification company, SGS, has invested in multiple sensitive and selective LC-MS/MS instruments for the quantification of proteins and peptide therapeutics at its lab in Poitiers, France.
The two systems, now installed and validated, are a combination of the AB SCIEX 6500+ and Shimadzu X2 UPLC, which offers a wide dynamic range and the ability to quantify multiple proteins simultaneously.
LC-MS/MS techniques have a number of advantages compared to standard conventions for protein and peptide quantitation, which are based on ligand-binding assays (LBAs), such as the enzyme-linked immunosorbent assay (ELISA).
Assay development can be time-consuming and expensive. In addition, LBA results are often plagued by interferences from antibody cross-reactivity.
“Mass spectrometry platforms have universal applicability, providing one technique for a large diversity of analytes,” said Walid Elbast, Director LC-MS at SGS Poitiers.
“All types of proteins and peptides can be quantified by LC/MS/MS without exception and a wide diversity of other biomolecules such as lipids and carbohydrates can also be quantified, providing researchers with a highly sensitive, selective and flexible bioanalytical platform.”
In addition to testing services for the bio/pharmaceutical market, SGS also provides services encompassing data management and statistics, PK/PD modelling and simulation, pharmacovigilance and regulatory consultancy.